The global hypertension drugs market is anticipated to grow at a considerable CAGR of 4% during the forecast period (2022-2028). The major players operating in the global hypertension drug market adopts various strategies including acquisitions, partnerships, collaborations, and new product launch to stay competitive in the market. For instance, in December 2021, Alembic Pharmaceuticals has received approval from the US Food and Drug Administration (USFDA) to market Selexipag tablets, which are used to treat high blood pressure. The USFDA has tentatively approved the company's abbreviated new drug application (ANDA) for Selexipag tablets in the strengths including 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg. Alembic's product is a generic version of Uptravi, a reference listed drug product (RLD). Selexipag Tablets are used to treat pulmonary arterial hypertension (PAH).
Browse the full report of "Hypertension Drug Market Size, Share & Trends Analysis Report Drug Type (Diuretics, ACE Inhibitors, Calcium Channel Blockers, Vasodilators, Beta-adrenergic Blockers, and Others), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and E-Commerce),Forecast 2022-2028" at https://www.omrglobal.com/industry-reports/hypertension-drug-market
In December 2021, Dr Reddy’s launched Dr Reddy's Laboratories announced that Valsartan pills, which are used to treat high blood pressure and heart failure, are now available in the US. The Valsartan pill has been authorised by the USGFDA as the generic therapeutic equivalent of Diovan. Dr. Reddy's Valsartan Tablets come in doses of 40 mg in a 30-count bottle and 80 mg, 160 mg, and 320 mg in a 60-count bottle. In April 2021, United Therapeutic’s Tyvaso (treprostinil) Inhalation Solution has been approved by the FDA for the treatment of individuals with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. Tyvaso was first licenced by the FDA in July 2009 for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) with the goal of improving exercise ability.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape - AstraZeneca Plc., Bayers AG, Daiichi Sankyo Company Ltd., Novartis International AG, Pfizer Inc., and many more.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Hypertension Drugs Market Report Segment
By Drug Type
By Distribution Channel
Global Hypertension Drugs Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World